ClinicalTrials.Veeva

Menu
W

Wichita Urology Group | Wichita, KS

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TAR-200
UGN-102
Androgen
MK-3475-905
TAR-210
Enfortumab
Vibegron
Cisplatin
Gemcitabine
Leuprolide Acetate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 18 total trials

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patie...

Active, not recruiting
Bladder Cancer
Urothelial Carcinoma
Drug: UGN-102

Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for men with advanced pr...

Enrolling
Metastatic Castration Resistant Prostate Cancer
Metastatic Castration-sensitive Prostate Cancer
Drug: prednisone
Drug: PRL-02 injection

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followe...

Enrolling
Bladder Cancer
Urologic Cancer
Other: n-dodecyl-B-D-maltoside
Drug: Cretostimogene Grenadenorepvec

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling
Bladder Cancer
Biological: Cetrelimab
Drug: TAR-200

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Active, not recruiting
Urinary Bladder Neoplasms
Drug: TAR-200
Biological: Cetrelimab

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Enrolling
Non-Muscle Invasive Bladder Neoplasms
Drug: Mitomycin C
Drug: Gemcitabine

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

Enrolling
Neurogenic Detrusor Overactivity
Drug: Vibegron

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling
Non-Muscle Invasive Bladder Cancer
Drug: Gemcitabine
Drug: MMC

A pivotal study to evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser...

Active, not recruiting
Urinary Stones
Device: Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer
Device: Standard Ureteroscopic Laser Lithotripsy
Locations recently updated

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Enrolling
High-risk Non-muscle Invasive Bladder Cancer
Biological: Pembrolizumab
Biological: BCG

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting
Urinary Bladder Cancer, Muscle-invasive
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Pembrolizumab

This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...

Active, not recruiting
Prostate Cancer
Drug: Leuprolide Acetate
Drug: Relugolix

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Merck Sharp & Dohme (MSD) logo
U
A
A
Astellas logo
Bayer logo
Bristol-Myers Squibb (BMS) logo
C
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems